Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: GlobalData | PRODUCT CODE: 1072944

Cover Image

PUBLISHER: GlobalData | PRODUCT CODE: 1072944

Pharmaceuticals Industry Deals and Trends in November 2021 - Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)

PUBLISHED:
PAGES: 91 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1000
PDF (Site License)
USD 1500
PDF (Global License)
USD 2000

Add to Cart

GlobalData's "Pharmaceuticals Industry Deals and Trends in November 2021 - Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2021. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharma Intelligence Center database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Product Code: GDHC0586MD

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Pharmaceuticals & Healthcare, Global, Deal Summary,

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, November 2021
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, November 2021
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, November 2021
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, November 2021

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, November 2021
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, November 2021
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, November 2021
  • 3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2021
  • 3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, June 2021 - November 2021
  • 3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), November 2021
  • 3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2021 - November 2021
  • 3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number of Deals, June 2021 - November 2021
  • 3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), June 2021 - November 2021
  • 3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2021 - November 2021

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2021

  • 4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2021
  • 4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2021
  • 4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), June 2021 - November 2021
  • 4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), June 2021 - November 2021
  • 4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), June 2021 - November 2021
  • 4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), June 2021 - November 2021

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

  • 5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, November 2021
  • 5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, November 2021
  • 5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, November 2021
  • 5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, November 2021
  • 5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, November 2021
  • 5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, November 2021
  • 5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, November 2021

6 Deal Summary by Geography

  • 6.1 Pharmaceuticals & Healthcare, North America Deals, November 2021
  • 6.2 Pharmaceuticals & Healthcare, Europe, Deals, November 2021
  • 6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, November 2021
  • 6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, November 2021

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors

  • 7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, June 2021 - November 2021
  • 7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, June 2021 - November 2021

8 Further Information

  • 8.1 Methodology
  • 8.2 About GlobalData
  • 8.3 Contact Us
  • 8.4 Disclosure information
  • 8.5 Disclaimer
Product Code: GDHC0586MD

List of Tables

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, November 2021
  • Table 3: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (%), November 2021
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2021
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2021 - November 2021
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2020- November 2021
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, November 2021
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, November 2021
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, June 2021 - November 2021
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number of Deals and Deal Values (%), October 2021
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2021-November 2021
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2021 - November 2021
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), November 2021
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2021 - November 2021
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2021 - November 2021
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), June 2021 - November 2021
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), June 2021 - November 2021
  • Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), June 2021 - November 2021
  • Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, June 2021 - November 2021
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m) June 2021 - November 2021
  • Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, November 2021
  • Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, November 2021
  • Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, November 2021
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2021 - November 2021

List of Figures

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals (%), November 2021
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), November 2021
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2021 - November 2021
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2021 - November 2021
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number of Deals (%), November 2021
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), November 2021
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2021 -November 2021
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2021 - November 2021
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2021 - November 2021
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2021 - November 2021
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2021 - November 2021
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2021 - November 2021
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2021 - November 2021
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2021 - November 2021
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number of Deals, June 2021 - November 2021
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), June 2021 - November 2021
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m) June 2021 - November 2021
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2021 - November 2021
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!